Investigational drug · Phase 3
Leuprorelin acetate
Also called: Leuprolide Open Label, DKF-MA102
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
359
Any phase or sponsor naming "Leuprorelin acetate"
First trial start
2014
Dec 17, 2014
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Leuprorelin acetate", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hormone Sensitive Prostate Cancer
- Prostate Cancer
- Cancer of the Prostate
- Endometriosis
- Advanced Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Endometriosis · Oncology · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Leuprorelin acetate" as an intervention, largest first.
TakedaTakeda (TAK)
NCT02167893 · 11,288 participants · Start Oct 2005 · Primary completion Dec 2010
Drug: Leuprorelin acetate · For: Prostate Cancer
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
Taipei Veterans General Hospital, TaiwanGovernment (non-federal)
NCT03778359 · 5,000 participants · Start Jan 1, 2005 · Primary completion Dec 31, 2015
Drug: Leuprorelin; Dienogest and 1 more · For: Endometriosis; Adenomyosis
Sites: Taipei County, Taiwan
- RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local SurgeryPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00541047 · 4,236 participants · Start Nov 2007 · Primary completion Jul 27, 2022
Drug: bicalutamide; goserelin acetate and 1 more · For: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction and 1 more
Sites: Kelowna, Canada; Vancouver, Canada; London, Canada · 58 sites in all
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04961996 · 4,170 participants · Start Aug 27, 2021 · Primary completion Aug 8, 2025
Drug: Giredestrant; Physician's Choice of Endocrine Therapy and 1 more · For: Early Breast Cancer
Sites: Daphne, Alabama; Bakersfield, California; Fullerton, California · 621 sites in all
TakedaTakeda (TAK)
NCT02134977 · 2,816 participants · Start Sep 2011 · Primary completion Mar 2015
Drug: Leuprorelin Acetate · For: Breast Cancer
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05050084 · 2,050 participants (planned) · Start Dec 6, 2021 · Primary completion Nov 11, 2026
Drug: Bicalutamide; Buserelin and 8 more · For: Prostate Adenocarcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 576 sites in all
- Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate CancerPivotal-lookingCompleted
Radiation Therapy Oncology GroupResearch network
NCT00002597 · 2,028 participants · Start Oct 1994 · Primary completion Jul 2011
Drug: flutamide; Zoladex and 1 more · For: Prostate Cancer
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 239 sites in all
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerPivotal-lookingActive, not recruiting
SWOG Cancer Research NetworkResearch network
NCT01674140 · 1,939 participants · Start Sep 12, 2013 · Primary completion Dec 1, 2022
Drug: anastrozole; everolimus and 5 more · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,458 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Leuprorelin Acetate for Spinal and Bulbar Muscular Atrophy: A Systematic Review of Clinical Efficacy, Long-Term Outcomes, and Safety Considerations.
Wang B, Wang I, Park C, et al. · Muscle Nerve 2026
- Novel GnRH analogue decorated paclitaxel and CQDs co-loaded theranostic zein nanoparticles for treatment of breast cancer: Formulation optimization, in vitro and in vivo evaluation.
Patel P, Yadav P, Sonone PR, et al. · Int J Biol Macromol 2026
- Gene Therapy for Metastatic Castration-Resistant Prostate Cancer Using the JC Polyomavirus (JCPyV) Virus-Like Particles as a Gene Delivery Vector.
Chou CC, Tseng CE, Lin YS, et al. · Cancer Med 2026
- Case Report: Immunotherapy-containing fertility-sparing treatment integrated with preimplantation genetic testing resulting in live birth in Lynch syndrome-associated endometrial cancer.
Zhao Y, Zhao Y, Hu T, et al. · Front Oncol 2026
- Meningioma enlargement associated with luteinizing hormone-releasing hormone agonist therapy: two cases and supporting in vitro evidence.
Ichinose T, Kinoshita M, Sakaguchi M, et al. · Brain Tumor Pathol 2026
- Spontaneous Expulsion of a Large Submucosal Fibroid in the Postpartum Period: A Report of a Rare Case.
Kyaw EMM, Naing EEP, Pann ML · Cureus 2026
Also in development for Hormone Sensitive Prostate Cancer
- MevrometostatPF-06821497Phase 33 trials
Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.